Effect of SGLT2i on Diabetic Retinopathy in Type 2 Diabetes Mellitus Patients
Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
A prospective, randomized, open-label, controlled clinical trial will be conducted at the
endocrinology department - Ain Shams University (ASU) hospital. Sixty patients will be
enrolled into the study. 30 of which will receive dapagliflozin 10mg tab once daily and the
other thirty will receive their standard antidiabetic therapy for 12 weeks.